Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2003
05/06/2003US6559148 Administering a therapeutically effective amount of a compound which is a P2Y purinoreceptor antagonist such as Basilen Blue
05/06/2003US6559139 Combination chemotherapy
05/06/2003US6559137 Characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient
05/06/2003US6559133 Administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular or acute coronary syndromes alone or with thromolytic, anticoagulants, antithrombotic or antiplatelet agents
05/06/2003US6558952 Expansion of preferential pancreatic cells; generate nutrient broth, inoculate with pancreatic cells and gastrin receptor ligand, monitor propagation of pancreatic cells
05/06/2003US6558950 Nucleotide sequences coding polypeptide for use in the treatment of programed cell death defects
05/06/2003US6558905 Diagnosing osteoporosis in humans; obtain tissue sample, extract nucleotide sequences, digest, incubate with marker probe, detect presence of preferential allele, presence of allele indicate osteoporosis
05/06/2003US6558702 Mixture of polymer and bisphosphonate compound
05/06/2003US6558694 Zinc chloride unit dose packaging, applicator, and method of use in treating cancer and other skin diseases
05/06/2003US6558675 Mutant human hepatitis B viral strain and uses thereof
05/06/2003US6558667 Therapy of patient suffering from a renal failure progressed to a stage at which an initiation of a dialysis therapy is required by combining a peritoneal dialysis and an administration of a spherical carbon
05/06/2003US6558666 Chromium-containing carbohydrase enzyme food supplement composition
05/06/2003US6558661 Inhibiting binding of interferon-gamma to its native receptor
05/06/2003CA2181048C A method for sustained and extended corneal analgesia
05/06/2003CA2115060C Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
05/06/2003CA2047802C Pharmaceutical compositions
05/02/2003EP1306672A2 Method of screening drug for hepatitis C
05/02/2003EP1306437A2 Delta opioid receptor genes
05/02/2003EP1306095A2 Methods and compositions for targeting the vasculature of solid tumors
05/02/2003EP1306093A1 Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient
05/02/2003EP1306091A2 Stimulation of beta cell proliferation
05/02/2003EP1306089A1 Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists
05/02/2003EP1306088A1 Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic
05/02/2003EP1306083A1 Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion
05/02/2003EP1305636A2 Screening method
05/02/2003EP1305635A2 Methods to identify compounds that modulate rage
05/02/2003EP1305425A2 Drug metabolizing enzymes
05/02/2003EP1305419A2 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
05/02/2003EP1305418A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
05/02/2003EP1305406A2 Modulation of gamma-secretase activity
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305340A2 Sequences for integrin alpha-8
05/02/2003EP1305330A1 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
05/02/2003EP1305329A1 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl)oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
05/02/2003EP1305322A2 Derivatives of branched-chain lipophilic molecules and uses thereof
05/02/2003EP1305309A1 Lactam inhibitors of factor xa which are useful for the treatment of thrombosis
05/02/2003EP1305304A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor
05/02/2003EP1305300A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments
05/02/2003EP1305295A1 Imidazole derivatives
05/02/2003EP1305057A1 Microparticulate biomaterial composition for medical use
05/02/2003EP1305051A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
05/02/2003EP1305048A2 Inhibitors of cellular efflux pumps of microbes
05/02/2003EP1305047A2 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
05/02/2003EP1305046A2 Regulators of ppardelta (beta) and their use in the treatment of obesity and insulin resistance
05/02/2003EP1305045A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
05/02/2003EP1305032A1 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
05/02/2003EP1305031A2 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
05/02/2003EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
05/02/2003EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
05/02/2003EP1305020A2 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
05/02/2003EP1305008A2 Improved forms of pharmaceutically active agents and method for manufacture thereof
05/02/2003EP1305007A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1304992A1 Topical gel delivery system
05/02/2003EP1304922A2 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring
05/02/2003EP1304921A2 Transgenic mice containing targeted gene disruptions
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1196167A4 Method of reducing neuronal injury or apoptosis
05/02/2003EP1189611A4 Cancer therapy
05/02/2003EP1096933B1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses
05/02/2003EP1021171B1 Delayed total release gastrointestinal drug delivery system
05/02/2003EP0999840B1 Use of a draflazine analogue for treating pain
05/02/2003EP0998272B1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant
05/02/2003EP0986396A4 Prion protein modulator factor (ppmf) and prion resistant animals
05/02/2003EP0983037B1 Antifungal nail lacquer
05/02/2003EP0979081A4 Composition and methods using an eutomer
05/02/2003EP0876146B1 Nucleoside analogs in combination therapy of herpes simplex infections
05/02/2003EP0786988B1 Use of nk1 receptor antagonists for preparing cardio-regulatory drugs
05/02/2003EP0775130B1 Method for the preparation of (+/-)-calanolide a and intermediates thereof
05/02/2003EP0724387B1 Angiotension ii receptor antagonists for the treatment of chronic anti-inflammatory diseases
05/01/2003WO2003035848A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
05/01/2003WO2003035847A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035670A2 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
05/01/2003WO2003035621A1 Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
05/01/2003WO2003035111A1 Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
05/01/2003WO2003035110A1 Treating vascular disease by inhibiting toll-like receptor-4
05/01/2003WO2003035108A1 Immunopotentiators in thermotherapy for cancer
05/01/2003WO2003035107A1 Enzyme inhibitors for inactivating allergens
05/01/2003WO2003035095A1 Use of histamine to treat liver disease
05/01/2003WO2003035081A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
05/01/2003WO2003035078A1 Combined use of catalytic antioxidants and glutathion or lipoic acid
05/01/2003WO2003035076A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
05/01/2003WO2003035074A1 Drugs comprising combination of triazaspiro[5,5]undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor
05/01/2003WO2003035069A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003WO2003035062A1 Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
05/01/2003WO2003035060A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003WO2003035055A1 Mch antagonists for the treatment of obesity
05/01/2003WO2003035050A2 Use of tyrosine kinase inhibitors for promoting hair growth
05/01/2003WO2003035049A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003WO2003035048A2 Methods for the treatment of osteoarthritis and compositions thereof
05/01/2003WO2003035047A2 Combinations comprising a selective cyclooxygenase-2 inhibitor
05/01/2003WO2003035046A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent
05/01/2003WO2003035040A1 Methods of treatment using a gastric retained gabapentin dosage
05/01/2003WO2003035039A1 Methods of treatment using a gastric retained losartan dosage
05/01/2003WO2003035030A1 Kit for the preparation of a pharmaceutical composition
05/01/2003WO2003035007A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
05/01/2003WO2003035002A2 Management of postoperative pain
1 ... 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 ... 1151